First day of trading in Sensidose AB

Today is the first day of trading in Sensidose AB, a Swedish pharmaceutical company which develops and sells individualised dosing of medicines for the medical treatment of Parkinson’s disease.

Sensidose has developed the drug Flexilev® which, in combination with the proprietary MyFID® dosing device, individualises and adjust the treatment of Parkinson's disease. The Company's vision is to improve the quality of life for patients with chronic diseases through improved individualised medication, leading to better efficacy and reduced side effects of given treatment. The Company is now in a growth phase with a focus on the development and launch of a new dosing device - ORAFID. The new dosing device aims to offer an optimal treatment approach also to patients in earlier stages of Parkinson's disease. The proceeds of the issue are mainly intended to realise the development of the ORAFID, which is planned to be launched in late 2023.

“Today we welcome Sensidose to Spotlight! The company has a unique treatment for Parkinson's and is now on an exciting growth journey where they intend to introduce a new dosing device. We look forward to following their journey, Head of Listing, Spotlight.

Press contact
Anders Eriksson, CEO
+46 79 006 65 66, ae@spotlightstockmarket.com

ABOUT SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight, it is easier and safer for companies to be listed. We offer an overall solution that increases the visibility of our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in approximately 160 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof, and Synthetic MR.
spotlightstockmarket.com